Skip to main content

Regeneron Pharmaceuticals EYLEA HD revenue

  • REGN · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$955.47+0.45%Close 13 Nov 2026 · Market value $102.5B

EYLEA HD revenue at Regeneron Pharmaceuticals came to $698.8M for the quarter to 30 Sep 2026, up 62.3% from a year earlier.

As Regeneron Pharmaceuticals reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 30 Oct 2026.

By quarter

$42.7MSep 2023$200.0MMar 2024$304.2MJun 2024$392.3MSep 2024$304.6MDec 2024$306.8MMar 2025$393.2MJun 2025$430.6MSep 2025$506.3MDec 2025$468.4MMar 2026$596.3MJun 2026$698.8MSep 2026
Regeneron Pharmaceuticals EYLEA HD revenue, every reported period
Period endingEYLEA HD revenueChange on a yearFiled
30 Sep 2026$698.8Mup 62.3%30 Oct 2026
30 Jun 2026$596.3Mup 51.7%30 Jul 2026
31 Mar 2026$468.4Mup 52.7%29 Apr 2026
31 Dec 2025$506.3Mup 66.2%4 Feb 2026
30 Sep 2025$430.6Mup 9.8%28 Oct 2025
30 Jun 2025$393.2Mup 29.3%1 Aug 2025
31 Mar 2025$306.8Mup 53.4%29 Apr 2025
31 Dec 2024$304.6M—5 Feb 2025
30 Sep 2024$392.3Mup 818.7%31 Oct 2024
30 Jun 2024$304.2M—1 Aug 2024
31 Mar 2024$200.0M—2 May 2024
30 Sep 2023$42.7M—2 Nov 2023
30 Jun 2023$0—3 Aug 2023
31 Mar 2023$0—4 May 2023
30 Sep 2022$0—3 Nov 2022

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Regeneron Pharmaceuticals: Collaboration revenue · Net product sales · Libtayo revenue · Lynozyfic revenue · EYLEA HD And EYLEA revenue · EYLEA revenue · Praluent revenue · Evkeeza revenue · financial statements

Every KPI and segment of REGN, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.